Table 2.
Crude event rates for severe ocular inflammation claims over time from intravitreal anti-VEGF injections for neovascular age-related macular degeneration, US.
| Time of injection | Ranibizumab |
Aflibercept |
||||
|---|---|---|---|---|---|---|
| Events, n | Injections, n | CERa (95% CI) |
Events, n | Injections, n | CERa (95% CI) |
|
| Nov 2011–Apr 2012 | 76 | 78,164 | 0.97 (0.75–1.19) |
19 | 17,461 | 1.09 (0.60–1.58) |
| May 2012–Oct 2012 | 77 | 65,075 | 1.18 (0.92–1.45) |
48 | 48,212 | 1.00 (0.71–1.28) |
| Nov 2012–Apr 2013 | 72 | 66,078 | 1.09 (0.84–1.34) |
118 | 65,688 | 1.80b (1.47–2.12) |
| May 2013–Aug 2013 | 47 | 44,330 | 1.06 (0.76–1.36) |
91 | 47,786 | 1.90b (1.51–2.30) |
aCERs compared by t-test between treatment groups.
b p < 0.05.
CI, confidence interval; CER, crude event rate per 1000 injections; VEGF, vascular endothelial growth factor.